TOMSK, RUSSIA / RankWire.AI / – Russian scientists have evaluated a bioactive coating aimed at enhancing the integration of titanium orthopedic implants with bone tissue. The formulation incorporates calcium phosphate derived from hydroxyapatite and contains nitrogen compounds linked to nitric oxide synthesis. Laboratory experiments demonstrated a notable increase in the survival rate of human mesenchymal stem cells on coated surfaces compared to uncoated titanium. The team analyzed the coating’s structure, chemical makeup, mechanical attributes, and biological response. Their peer-reviewed results appeared in Applied Surface Science in 2026.
The experimental coatings were produced by Tomsk Polytechnic University through reactive magnetron sputtering of a hydroxyapatite target within a vacuum chamber. During deposition, the researchers varied the nitrogen and argon gas mixture to observe how each ratio influenced the surface properties. Five conditions were tested, ranging from pure nitrogen to pure argon. Measurements included coating thickness, surface morphology, hardness, wettability, and chemical composition. Laboratory assessments also evaluated how living human cells responded to the modified titanium surfaces.
Results indicated that the amount of argon influenced several physical characteristics of the coatings. Surfaces deposited in pure argon exhibited higher density and hardness compared to those created with pure nitrogen. An increase in coating thickness was also observed as the argon proportion grew. Chemical analysis detected nitrogen-carbon and nitrogen-oxygen bonds on the modified surfaces. The study further compared human mesenchymal stem cells grown on coated titanium with those on uncoated titanium, analyzing cell viability and markers associated with bone cell development.
Enhanced Cell Survival Demonstrated in Coating Tests
Laboratory tests revealed significantly improved cell survival on coated titanium surfaces compared to uncoated samples, according to the research. After seven days, coatings with higher nitrogen levels also suppressed activity in certain genes linked to early bone-cell differentiation. Despite this, the cells retained their ability to form bone tissue. The biological responses were assessed under controlled laboratory conditions using human mesenchymal stem cells. It is important to note that the study did not involve testing in clinical settings or evaluating the performance of medical implants in patients.
The biomedical evaluation was carried out by Immanuel Kant Baltic Federal University and Siberian State Medical University, with additional contributions from Saint Petersburg State University. The project received backing from Russia’s state science program. The focus was on identifying gas mixtures that could produce coatings with optimal physical, chemical, and biological properties. Hydroxyapatite is already used in implant coatings because its calcium phosphate structure closely resembles the mineral found in human bone.
The study remains in the laboratory research phase
The researchers outlined plans for further testing beyond the initial seven-day cell culture experiments. Future studies aim to monitor stem cells over 10 to 28 days, investigate the dissolution rate of the coatings, and measure nitric oxide release into surrounding tissues in vivo. These additional investigations were not part of the published laboratory results. Currently, the research is focused on coated titanium substrates, their physical and chemical characteristics, and in vitro cell responses, rather than clinical outcomes in orthopedic patients.
The findings offer comprehensive laboratory data on how variations in nitrogen and argon ratios influence calcium phosphate coatings on titanium. Differences in thickness, density, hardness, chemical bonds, and cellular responses across the tested gas mixtures were documented. The study confirmed that coated samples supported higher stem-cell survival than uncoated titanium under experimental conditions. Nonetheless, the research remains preclinical, and the published experiments do not establish safety or efficacy in humans. Additional biological testing is planned to evaluate properties that were not examined in this initial phase.